Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term

Industry Overview - Companies in synthetic biology engineer biological systems for applications in pharmaceuticals and agriculture, utilizing genetic engineering and biotechnology techniques to create novel organisms and processes, with significant growth potential in curing genetic diseases and extending human lifespan [1] - The genomics and synthetic biology sectors are attracting substantial interest from venture capitalists and institutional investors due to their potential for innovation and tailored treatments based on genetic makeup [8][21] Company Highlights - CRISPR Therapeutics is leveraging its CRISPR/Cas9 gene-editing platform to develop therapies for hemoglobinopathies, cancer, and diabetes, achieving a milestone with the first-ever approval for a CRISPR/Cas9 gene-edited therapy, Casgevy, in the UK for treating sickle cell disease and transfusion-dependent beta-thalassemia [3][12][23] - Monte Rosa Therapeutics is focused on developing small-molecule precision medicines that utilize the body's mechanisms to selectively degrade proteins relevant to various diseases, including MYC-driven tumors and autoimmune diseases [5][11] - Immunocore Holdings is developing a novel class of T cell receptor bispecific immunotherapies for cancer and autoimmune diseases, with its product KIMMTRAK already in use for treating unresectable or metastatic uveal melanoma [13][25] Price Target and Upside Potential - The average short-term price target for CRISPR Therapeutics indicates a potential increase of 136.7% from the last closing price of $28.32, with a maximum upside of 253.1% and a downside of 15.3% [4] - Monte Rosa Therapeutics has a projected price target increase of 161.1% from a closing price of $6.93, suggesting a maximum upside of 188.6% with no downside [14] - Rigel Pharmaceuticals shows a potential price increase of 82.1% from a closing price of $17.09, with a maximum upside of 233.5% and a downside of 18.1% [18] - Castle Biosciences has a projected price target increase of 51.4% from a closing price of $27.53, indicating a maximum upside of 81.6% with no downside [20] Investment Recommendations - Five small and mid-sized genomics and synthetic biology stocks are recommended for investment, including CRISPR Therapeutics, Immunocore Holdings, Monte Rosa Therapeutics, Rigel Pharmaceuticals, and Castle Biosciences, all carrying favorable Zacks Ranks [7][9]